Where Reckitt (Schiff / Neuriva) Stands: A Strategic Assessment for Industry Partners

United Kingdom — 1 September 2026

Reckitt's presence in the supplement sector, particularly through its Schiff Nutrition International portfolio including Move Free and Neuriva, offers a compelling case study for the B2B industry. As an FMCG giant, Reckitt brings significant marketing muscle and distribution networks to categories often characterised by scientific nuance and evolving regulatory landscapes. Its approach highlights the tension between broad consumer appeal and the rigorous substantiation increasingly demanded for health products, providing valuable insights into market dynamics and competitive strategies.

Company Snapshot

Reckitt Benckiser Group plc, headquartered in Slough, UK, is a multinational consumer goods company. While specific supplement division revenues are not publicly disaggregated, the company's annual turnover is substantial, running into the billions of pounds. Key health brands include Strepsils, Gaviscon, Dettol, and the Schiff Nutrition portfolio, which features Move Free, Neuriva, Airborne, and MegaRed. Reckitt operates in over 60 countries, with products sold in nearly 200, and employs approximately 40,000 people globally.

Strategic Position and Recent Moves

Reckitt's strategy in supplements centres on leveraging established brand equity and R&D capabilities to drive growth in key health segments. The acquisition of Schiff Nutrition International in 2012 for approximately £1.4 billion provided a strong foothold in the US market, particularly in joint health (Move Free) and cognitive support (Neuriva). In the last 12-24 months, Reckitt has focused on line extensions and marketing campaigns for these brands, aiming to maintain relevance and market share. For instance, Neuriva has seen new product formats and ingredient combinations introduced, such as Neuriva Plus and Neuriva Brain Health Gummies, seeking to broaden its consumer base beyond traditional capsules. Move Free has also expanded its range to include products targeting specific joint concerns or offering different delivery formats. While no major supplement-specific acquisitions have been reported in this recent period, the company consistently invests in digital marketing and retail partnerships to enhance product visibility and accessibility across its vast distribution network.

What Manufacturers Can Learn

Reckitt's strategy underscores the power of brand recognition and robust marketing in driving consumer adoption, even in categories where scientific substantiation is complex. For contract manufacturers and ingredient suppliers, this highlights a sustained demand for scalable production of established ingredients, often combined with innovative delivery systems. The emphasis on line extensions for brands like Neuriva and Move Free indicates that consumer interest is broad, extending beyond initial product offerings into tailored solutions and convenient formats. In our experience manufacturing for diverse brands, the briefs we receive increasingly ask for not just efficacy, but also enhanced palatability and novel forms, such as gummies or liquid shots, which Reckitt effectively employs. This points to a market where product differentiation through experience and convenience is as crucial as the core formulation. Understanding how large players manage extensive product portfolios and global supply chains also offers valuable lessons in operational efficiency and risk management.

Risks and Headwinds

Reckitt’s supplement division faces several significant challenges. The cognitive health and joint care categories, while growing, are subject to intense scientific scrutiny regarding ingredient efficacy and approved health claims. Brands like Neuriva, which make cognitive support claims, often attract attention from regulatory bodies and consumer watchdogs, necessitating rigorous scientific backing and careful communication. Competition is fierce, with both established pharmaceutical companies and agile direct-to-consumer brands vying for market share. Furthermore, the broader reputational risks associated with an FMCG giant can spill over into specific product lines if not managed carefully. Economic pressures affecting consumer spending on discretionary health products also represent a constant headwind, requiring careful pricing strategies and value propositions. Maintaining a balance between accessible pricing and premium positioning for scientifically-backed ingredients is a perpetual challenge.

The B2B Verdict

Supplement businesses should certainly watch Reckitt (Schiff / Neuriva) closely. Its scale and strategic decisions offer a barometer for market trends, particularly in how mainstream consumers engage with complex health categories. Partnering opportunities might exist for ingredient suppliers offering novel, well-substantiated compounds, or for manufacturers capable of high-volume, compliant production of innovative formats. For smaller brands, competing directly on brand recognition is challenging; instead, focus should be on niche specialisation, superior scientific backing, or agile market responsiveness. Reckitt's journey illustrates the enduring power of brand investment alongside the increasing imperative for scientific integrity in the supplement industry.